News Network

Post-Conference Perspectives: Balstilimab In The Treatment of Cervical Cancer

November 30th 2021

Emerging Therapies in Relapsed or Refractory Multiple Myeloma

November 12th 2021

Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

Updates in CLL: Optimizing Testing Rates

November 4th 2021

Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.

Approval of Tisotumab Vedotin in The Treatment of Cervical Cancer

November 1st 2021

Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

Antibody-Drug Conjugates in NSCLC: Update on TROPION-PanTumor01 Data

October 22nd 2021

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.

Advanced HER2-Positive Breast Cancer: Update on Destiny-Breast03 Data

October 21st 2021

Mark Pegram, MD, and Sara Tolaney, MD, review data from DESTINY-Breast03 trial and implications of these data for treatment of patients with HER2+ breast cancer going forward.

Screening and Treatment for Lung Cancer: What's Next?

October 13th 2021

The second part of the webinar Lung Cancer Screening and Treatment: What's Next? focuses on the review of lung cancer screening and treatment status amid the COVID-19 pandemic. Participating faculty include Albert Rizzo, MD, FCCP, FACP, FAASM; James L. Mulshine, MD; Andrea Borondy Kitts, MS, MPH; and Sandip Patel, MD.

New Treatment Options in Chronic GVHD

October 8th 2021

An expert hematologist/oncologist will highlight the traditional treatment options, unmet needs, and recent advances and approvals in chronic graft vs host disease. Clinical trials will be described as well as novel agents on the horizon.

Updates in CLL: A Closer Look at Adverse Events

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, discuss adverse events associated with treating chronic lymphocytic leukemia, particularly when utilizing BTK inhibitors.

Update from HER2CLIMB in Relapsed Refractory HER2-Positive Breast Cancer

September 8th 2021

Implications for treating patients with progressive, unresectable locally advanced or metastatic HER2-positive breast cancer with tucatinib in combination with capecitabine and trastuzumab.

Post-Conference Perspectives: Chronic Lymphocytic Leukemia

August 16th 2021

Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.

Rare Drivers in Metastatic Non-Small-Cell Lung Cancer with a Focus on EGFR Exon 20 Insertion Mutations

July 28th 2021

Expert thoracic oncologists discuss the importance of comprehensive molecular testing and optimal use of novel targeted agents in metastatic non-small cell lung cancer.

Post-Conference Perspectives: Myeloproliferative Neoplasms

July 28th 2021

Key opinion leaders in the treatment of myeloproliferative neoplasms, Pankit Vachhani, MD, and Jamile Shammo, MD, share expert perspectives on ruxolitinib for patients with primary myelofibrosis and polycythemia vera.

Advanced Prostate Cancer: PSMA-Targeted Radioligand Therapies

July 23rd 2021

PSMA-Targeted Radioligand Therapies in Advanced Prostate Cancer

July 23rd 2021

The rationale behind the use of lutetium-177-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The Evolving Role of NGS and Germline Sequencing in Patients with Advanced and Metastatic Cancer

July 22nd 2021

Experts discuss recent data on next generation sequencing and germline testing in patients with advanced and metastatic cancer.

Uveal Melanoma

July 20th 2021

Drs Richard D. Carvajal and Marlana M. Orloff describe the rationale for treating uveal melanoma with tebentafusp and provide insight on assessing treatment response and managing treatment-related adverse events.

Tipifarnib in HRAS-mutant Head and Neck Squamous Cell Carcinoma

July 19th 2021

Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.

Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer

July 15th 2021

Sara A. Hurvitz, MD, discusses updated results of the HER2CLIMB trial of tucatinib in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer.

Antibody-Drug Conjugates in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

July 13th 2021

Best practices when prescribing and managing antibody-drug conjugate therapy as treatment for relapsed/refractory diffuse large B-cell lymphoma.